Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Jordan Gauthier1

  • 1Fred Hutchinson Cancer Research Center, Seattle, WA, États-Unis.

Bulletin Du Cancer
|January 29, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026
Same author

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Transplantation and cellular therapy·2026
Same author

Erratum: Novel R Shiny Tool for Survival Analysis With Time-Varying Covariate in Oncology Studies: Overcoming Biases and Enhancing Collaboration.

JCO clinical cancer informatics·2026
Same author

Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.

Nature communications·2026
Same author

Fear of Cancer Recurrence in Hematopoietic Cell Transplantation Survivors.

Transplantation and cellular therapy·2026
Same author

Novel R Shiny Tool for Survival Analysis With Time-Varying Covariate in Oncology Studies: Overcoming Biases and Enhancing Collaboration.

JCO clinical cancer informatics·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Chimeric antigen receptor (CAR) T-cell therapy, a promising cancer treatment, has seen increased accessibility in the US since 2017. This summary outlines current US practices for patient selection for CAR T-cell therapy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Chimeric antigen receptor (CAR) T-cell therapy research has been ongoing in the US since the 1980s.
  • The 2017 approval of Kymriah (tisagenlecleucel) marked a significant milestone, expanding access beyond clinical trials.
  • CAR T-cell therapy represents a revolutionary therapeutic approach in oncology.

Purpose of the Study:

  • To provide a practical overview of current practices in the United States for CAR T-cell therapy.
  • To guide clinicians in considering patient eligibility for CAR T-cell therapy.
  • To summarize the evolving landscape of CAR T-cell therapy in clinical settings.

Main Methods:

  • Review of current clinical practices and guidelines in the US.
  • Analysis of patient selection criteria for CAR T-cell therapy.
Keywords:
Adoptive t-cell therapyChimeric antigen receptor therapyCytokine release syndromeHematological malignanciesHémopathies malignesNeurotoxicityNeurotoxicitéReviewRevueSolid tumorsSyndrome de libération de cytokinesThérapie adoptive des lymphocytes TThérapie de récepteur antigénique chimériqueTumeurs solides

Related Experiment Videos

  • Synthesis of information on the practical application of CAR T-cell therapy.

    • Main Results:

    • CAR T-cell therapy is increasingly accessible in the US following regulatory approvals.
    • Established criteria guide the selection of patients suitable for this advanced treatment.
    • Practical considerations are crucial for successful implementation of CAR T-cell therapy.

    Conclusions:

    • CAR T-cell therapy is a rapidly advancing field with growing clinical application.
    • Understanding current US practices is essential for effective patient management.
    • The accessibility of CAR T-cell therapy signifies a major therapeutic advancement.